Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery
Completed
Bausch & Lomb Incorporated
Phase 3
2003-05-01
The primary objective of this study was to investigate the efficacy of bromfenac sodium
ophthalmic solution 0.09% for treatment of post-operative ocular inflammation in subjects who
undergo cataract extraction and intraocular lens implantation. The secondary objective was to
investigate the safety and tolerability of the same.
Treatment of Acute Pseudophakic Cystoid Macular Edema: Bromfenac 0.09% Versus Diclofenac Sodium 0.1% Versus Ketorolac Tromethamine 0.5%
Completed
Bp Consulting, Inc
Phase 4
2008-01-01
To compare bromfenac 0.09%, diclofenac sodium 0.1%, and ketorolac tromethamine 0.5%
ophthalmic solutions for the treatment of acute pseudophakic CME after cataract surgery.
Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery
Completed
InSite Vision
Phase 2
2011-07-01
The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium
in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to
routine cataract surgery.
Aqueous Humor Concentration of InSite Vision (ISV) 303 (Bromfenac in DuraSite) to Bromday Once Daily (QD) Prior to Cataract Surgery
Completed
Sun Pharma Global FZE
Phase 2
2011-07-01
The purpose of this study is to evaluate the aqueous humor concentration of bromfenac sodium
in subjects administered multiple topical ocular doses of ISV-303 or Bromday™ QD prior to
routine cataract surgery.
Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil
Completed
Fundação de Amparo à Pesquisa do Estado de São Paulo
Phase 4
2014-08-01
The purpose of this study is to assess whether the switch from branded to generic warfarin or
between different generic warfarin tablets may cause fluctuation in the results of
coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing
them to unnecessary risks.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
